TL;DR
This review synthesizes current research on dopamine (DA) and its receptors (DRs) in digestive system diseases, highlighting their crucial roles beyond the brain. It explores how DA signaling impacts everything from esophageal function to intestinal inflammation and liver disease, suggesting that targeting DA pathways could offer novel therapeutic strategies for a range of gastrointestinal conditions.
What Problem Does This Paper Address?
While dopamine's role in neurological disorders like Parkinson's and schizophrenia is well-established, its involvement in the digestive system has only recently gained significant attention. The "brain-gut axis" concept has spurred research into how neurotransmitters, including dopamine, influence gastrointestinal physiology and pathology. However, a comprehensive understanding of dopamine's multifaceted roles across various digestive diseases and the therapeutic potential of targeting its receptors remains fragmented. This paper aims to consolidate this growing body of research, providing a unified overview of dopamine's impact on the esophagus, stomach, intestines, pancreas, and liver, and discussing the implications for drug development.
Methods
This paper is a comprehensive review, not an experimental study. The authors synthesized information from a wide range of published research articles. They analyzed existing literature on the biochemical and pharmacological properties of dopamine and its receptors, and then systematically reviewed studies investigating their roles in specific digestive system diseases. The review also examines the therapeutic applications of existing dopamine receptor modulators (agonists and antagonists) and discusses their potential for treating these conditions.
Datasets
Not discussed in the paper. This is a review article that synthesizes existing research, rather than presenting new experimental data or datasets.
Key Insights and Ideas
- Dopamine is a Gut Player: Beyond its well-known role in the brain, dopamine is synthesized in significant amounts within the gastrointestinal tract, particularly in mesenteric organs, acting as a crucial local signaling molecule.
- Receptor Diversity is Key: Dopamine exerts its effects by binding to various dopamine receptors (DRD1-DRD5), which are differentially expressed across digestive tissues, leading to diverse physiological outcomes.
- Brain-Gut Axis in Action: Dopamine signaling in the gut influences a wide array of functions, including digestion, immune regulation, and intestinal endocrine signaling, underscoring the interconnectedness of the brain and gut.
- Therapeutic Potential Abounds: Existing drugs that modulate dopamine receptors, originally developed for neurological conditions, are showing promise in treating digestive diseases like GERD, peptic ulcers, and even certain cancers.
- Emerging Roles in Disease: Dopamine and its receptors are implicated in the pathogenesis of a broad spectrum of digestive diseases, including inflammatory bowel disease, pancreatic cancer, and liver disease, suggesting them as potential diagnostic markers and therapeutic targets.
Key Results
The review highlights that:
- Esophageal Diseases: Dopamine receptor antagonists like domperidone are used to treat gastroesophageal reflux disease (GERD) by promoting gastric emptying and increasing lower esophageal sphincter tone.
- Gastric Diseases: Dopamine plays a protective role against gastric ulcers and influences gastric acid secretion. DRD2 antagonists like sulpiride can reduce gastric acid and inhibit ulcer development.
- Intestinal Diseases: Dopamine is vital for intestinal motility, exocrine secretion, and immune responses. Reduced dopamine levels are observed in inflammatory bowel disease, and DRD2 agonists show promise in reducing inflammation and ulceration.
- Biliary and Pancreatic Diseases: Dopamine receptors are expressed in the pancreas and are involved in regulating insulin secretion. Dopamine has been shown to inhibit inflammatory responses in pancreatitis and promote tumor growth in cholangiocarcinoma. DRD2 inhibitors are being explored for pancreatic cancer treatment.
- Liver Disease: Dopamine plays a role in suppressing autoimmune hepatitis. DRD2 antagonists can normalize fibrotic processes in non-alcoholic steatohepatitis. Dopamine also promotes the proliferation and metastasis of hepatocellular carcinoma (HCC) cells, with DRD1 expression linked to poor prognosis.
Limitations and Future Work
The authors acknowledge several limitations and suggest future directions:
- Limited Clinical Translation: While many DA and DR modulators show promise in preclinical studies, their clinical application for digestive system diseases is still limited. Most successful applications are in animal models, and translation to human practice is a significant challenge.
- Mechanistic Understanding: The precise mechanisms underlying dopamine's effects in many digestive diseases are not fully understood and require further in-depth research.
- Developing New Modulators: Developing novel DA and DR modulators specifically for digestive system diseases remains a challenging but crucial task.
- "Old Drugs for New Use": The review notes the trend of repurposing existing drugs, which can reduce research costs and accelerate clinical application.
- Multidisciplinary Collaboration: To advance clinical practice, close collaboration among multidisciplinary scientists and clinicians is essential to gain a deeper understanding of DA and DR functions and their roles in digestive system diseases.
- Diagnostic and Prognostic Biomarkers: Further research is needed to explore the potential of DA and DRs as diagnostic markers and prognostic indicators for various digestive conditions.
Summary updated